Call Now

Human APOL1 / apolipoprotein L1 Protein (His Tag)

APO-L,APOL,APOL-I,APOL1,FSGS4

Catalog Number P13910-H08B
Organism Species Human
Host Baculovirus-Insect Cells
Synonyms APO-L,APOL,APOL-I,APOL1,FSGS4
Molecular Weight The secreted recombinant human APOL1 consists of 381 amino acids and predicts a molecular mass of 42.5 KDa. The apparent molecular mass of the protein is approximately 44 KDa in SDS-PAGE under reducing conditions due to glycosylation.
predicted N Glu 28
SDS-PAGE
Purity > 91 % as determined by SDS-PAGE
Protein Construction A DNA sequence encoding the human APOL1 (Met 1-Leu398) (Q2KHQ6) was expressed, with a C-terminal polyhistidine tag.
Bio-activity
Research Area Developmental Biology |Metabolism |Pathways and Processes |Metabolic signaling pathways |Lipid and lipoprotein metabolism |Lipoprotein metabolism |
Formulation Lyophilized from sterile 20mM Tris, 500mM NaCl, pH 7.4, 10% gly, 3mM DTT
1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background APOL1, also known as apolipoprotein L1, is a minor apoprotein component of HDL (High-density lipoprotein) or 'good cholesterol' which is synthesized in the liver and also in many other tissues, including pancreas, kidney, and brain. APOL1 belongs to the apolipoprotein L family. It may play a role in lipid exchange and transport throughout the body. It may also participate in reverse cholesterol transport from peripheral cells to the liver. Defects in APOL1 are the cause of focal segmental glomerulosclerosis type 4 (FSGS4). It is a renal pathology defined by the presence of segmental sclerosis in glomeruli and resulting in proteinuria, reduced glomerular filtration rate and edema. Renal insufficiency often progresses to end-stage renal disease, a highly morbid state requiring either dialysis therapy or kidney transplantation.
Reference
  • Genovese G, et al. (2010) Association of Trypanolytic ApoL1 Variants with Kidney Disease in African-Americans. Science. 329 (5993): 841-5.
  • Tzur S, et al. (2010) Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Human Genetics 128 (3): 345-50.
  • Hu CA, et al. (2012) Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease. FEBS Lett. 586 (7): 947-55.
  • Papeta N, et al. (2011) APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol. 22 (11): 1991-6.
  • Fine DM, et al. (2012) APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease. J Am Soc Nephrol. 23 (2): 343-50.